KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Adaptive Biotechnologies (ADPT) Accumulated Depreciation & Amortization (2018 - 2025)

Adaptive Biotechnologies' Accumulated Depreciation & Amortization history spans 7 years, with the latest figure at $87.8 million for Q4 2024.

  • For Q4 2024, Accumulated Depreciation & Amortization rose 19.91% year-over-year to $87.8 million; the TTM value through Dec 2024 reached $87.8 million, up 19.91%, while the annual FY2024 figure was $87.8 million, 19.91% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2024 was $87.8 million at Adaptive Biotechnologies, up from $73.2 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $87.8 million in Q4 2024 and bottomed at $24.4 million in Q4 2020.
  • The 5-year median for Accumulated Depreciation & Amortization is $54.4 million (2022), against an average of $55.2 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization skyrocketed 50.03% in 2022 before it grew 19.91% in 2024.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $24.4 million in 2020, then soared by 48.58% to $36.2 million in 2021, then soared by 50.03% to $54.4 million in 2022, then skyrocketed by 34.75% to $73.2 million in 2023, then increased by 19.91% to $87.8 million in 2024.
  • Per Business Quant, the three most recent readings for ADPT's Accumulated Depreciation & Amortization are $87.8 million (Q4 2024), $73.2 million (Q4 2023), and $54.4 million (Q4 2022).